Amgen (NASDAQ: AMGN) Faces FDA Drug Withdrawal Proposal Ahead of Q1 Results

Amgen Inc. (NASDAQ: AMGN) shares slipped $1.55 (0.46%) to $338.02 on Wednesday, with sentiment weighed by a regulatory setback after the FDA's Center for Drug Evaluation and Research proposed withdrawing approval for Tavneos, the company's treatment for a rare form of vasculitis. Amgen has responded to the proposal, though the outcome remains subject to the FDA's formal review process.

Key Developments at a Glance

• Current price: $338.02 | Previous close: $339.57
• 52-week range: $261.43 – $391.29, placing the stock roughly mid-range
• Market cap: $182.2B
• Trailing P/E: 23.8x | Forward P/E: 14.5x — a meaningful compression suggesting the market expects profitability improvement ahead
• Net margin: 21.0% | Gross margin: 70.8% | Operating margin: 30.6%
• Revenue growth (YoY): 8.6% | Net income growth (YoY): 112.1%
• SEC 8-K filing (2026-04-22): Disclosed a departure or appointment of directors/officers (Item 9.01)

What Drove the Move

The proposed Tavneos withdrawal by the FDA is a material regulatory development for Amgen (NASDAQ: AMGN), as it introduces uncertainty around a product the company had positioned for a niche but meaningful patient population. Amgen has publicly responded to the FDA's proposal, signaling it intends to contest or engage in the process rather than accept an immediate withdrawal.

Separately, Amgen is also participating in a pioneering FDA initiative involving two studies where trial data will be shared with FDA scientists in real time alongside AstraZeneca — a development that underscores the company's ongoing engagement with regulators on innovation, even as the Tavneos situation creates near-term headline pressure.

Wall Street View

Analyst sentiment on Amgen (NASDAQ: AMGN) remains broadly constructive. As of the April 2026 consensus, 6 analysts rate the stock Strong Buy, 15 Buy, 19 Hold, 2 Sell, and 1 Strong Sell. Compared to the March 2026 period — which showed the same Strong Buy and Buy counts with one fewer Hold — the distribution has been essentially stable, suggesting the Tavneos news has not yet prompted a material re-rating among covering analysts.

Investor Takeaway

With a forward P/E of 14.5x sitting well below the trailing multiple of 23.8x, the market appears to be pricing in continued profitability improvement for Amgen (NASDAQ: AMGN) — supported by 8.6% revenue growth and a 112.1% year-over-year rise in net income. The Tavneos FDA proposal introduces a regulatory overhang that warrants monitoring, but the broad analyst consensus leans positive, and the company's engagement with the FDA on real-time clinical trial data sharing reflects a constructive regulatory posture overall.